References
- Revlimid (lenalidomide) [package insert]Summit, NJ, USACelgene Corporation2015
- Revlimid (lenalidomide) [summary of product characteristics]Uxbridge, UKCelgene Europe Ltd2015
- PalumboAFreemanJWeissLFenauxPThe clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromesExpert Opin Drug Saf201211110712022066855
- ListADewaldGBennettJLenalidomide in the myelodysplastic syndrome with chromosome 5q deletionN Engl J Med2006355141456146517021321
- FenauxPGiagounidisASelleslagDA randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5qBlood2011118143765377621753188
- NardoneBWuSGardenBCWestDPReichLMLacoutureMERisk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysisClin Lymphoma Myeloma Leuk201313442442923769670
- KomrokjiRSListAFRole of lenalidomide in the treatment of myelodysplastic syndromesSemin Oncol201138564865721943671
- LacoutureMEMechanisms of cutaneous toxicities to EGFR inhibitorsNat Rev Cancer200661080381216990857
- NardoneBNicholsonKNewmanMHistopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patientsClin Cancer Res201016174452446020732960
- DueckGChuaNPrasadAInterim report of a phase 2 clinical trial of lenalidomide for T-cell non-hodgkin lymphomaCancer2010116194541454820572046
- SivendranSLatifAMcBrideRBAdverse event reporting in cancer clinical trial publicationsJ Clin Oncol2014322838924323037
- HazellLShakirSAUnder-reporting of adverse drug reactions: a systematic reviewDrug Saf200629538539616689555
- FontanarosaPBRennieDDeAngelisCDPostmarketing surveillance – lack of vigilance, lack of trustJAMA2004292212647265015572723
- GiagounidisAFenauxPMuftiGJPractical recommendations on the use of lenalidomide in the management of myelodysplastic syndromesAnn Hematol200887534535218265982